免疫チェックポイント阻害薬治療における様々な癌種患者の免疫関連有害事象のパターン

Matthew J Slaught¹, Dalia Kaakour², Armon Azizi¹

¹University of California Irvine School of Medicine, Irvine, CA, USA.

Future oncology (London, England)

|December 21, 2025

要旨

Aims:

To investigate the association between primary cancer type and the tissues affected by immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs).

Patients & Methods:

A retrospective chart review was conducted on 241 patients representing 262 treatment lines involving ICIs at a single institution.

Results:

No significant association was found between cancer type and tissue-specific irAEs. irAE incidence was higher with combination PD-1/CTLA-4 inhibitors vs. PD-1 inhibitors alone (61% vs. 46%, p = 0.042). Median time to first irAE was 7.88 months for PD-1 monotherapy versus 2.30 months for combination therapy (log-rank p = 0.00011), a difference of 5.58 months.

Conclusions:

Primary cancer type was not significantly associated with tissue-specific irAEs in ICI-treated patients. The 5.58-month difference in median time to irAE onset has important implications for monitoring protocols. Further research is needed to identify factors predicting irAE patterns and severity.

キーワード:

CTLA-4阻害薬免疫チェックポイント阻害薬 PD-1阻害薬癌免疫療法併用免疫療法免疫関連有害事象後ろ向きコホート研究

さらに関連する動画

09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

984

07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.0K

関連する概念動画

01:27

Tumor Immunotherapy

1.7K

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

1.7K

01:27

Cytotoxic T Cells-mediated Immune Response

6.4K

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

6.4K